Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Walvax Biotech Soars after ChiNext IPO

publication date: Nov 12, 2010
Yunnan Walvax Biotechnology completed its IPO on the Shenzhen ChiNext Exchange, pricing 25 million shares at 95 RMB each ($14.32). The offering raised 2.375 billion RMB ($358 million). In open market trading, investors pushed the shares substantially higher. Walvax opened at 150 RMB and closed at 136.35, a gain of 44% for those who participated in the offering. The rise gives Walvax a market capitalization of 13.6 billion RMB ($2 billion). More details....


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here